|   | 
      
      
        | 
           
			 | 
        
          A BILL TO BE ENTITLED
         | 
      
      
        | 
           
			 | 
        
          AN ACT
         | 
      
      
        |   | 
      
      
        | 
           
			 | 
        relating to consent requirements for the prescription of certain  | 
      
      
        | 
           
			 | 
        psychoactive medications to residents of nursing facilities and  | 
      
      
        | 
           
			 | 
        related institutions. | 
      
      
        | 
           
			 | 
               BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | 
      
      
        | 
           
			 | 
               SECTION 1.  Section 242.505, Health and Safety Code, is  | 
      
      
        | 
           
			 | 
        amended by amending Subsection (c) and adding Subsections (c-1) and  | 
      
      
        | 
           
			 | 
        (c-2) to read as follows: | 
      
      
        | 
           
			 | 
               (c)  Subject to Subsection (c-1), consent [Consent] to the  | 
      
      
        | 
           
			 | 
        prescription of psychoactive medication given by a resident or by a  | 
      
      
        | 
           
			 | 
        person authorized by law to consent on behalf of the resident is  | 
      
      
        | 
           
			 | 
        valid only if: | 
      
      
        | 
           
			 | 
                     (1)  the consent is given voluntarily and without  | 
      
      
        | 
           
			 | 
        coercive or undue influence; | 
      
      
        | 
           
			 | 
                     (2)  the person prescribing the medication, [or] that  | 
      
      
        | 
           
			 | 
        person's designee, or the facility's medical director provided the  | 
      
      
        | 
           
			 | 
        following information, in a standard format approved by the  | 
      
      
        | 
           
			 | 
        department, to the resident and, if applicable, to the person  | 
      
      
        | 
           
			 | 
        authorized by law to consent on behalf of the resident: | 
      
      
        | 
           
			 | 
                           (A)  the specific condition to be treated; | 
      
      
        | 
           
			 | 
                           (B)  the beneficial effects on that condition  | 
      
      
        | 
           
			 | 
        expected from the medication; | 
      
      
        | 
           
			 | 
                           (C)  the probable clinically significant side  | 
      
      
        | 
           
			 | 
        effects and risks associated with the medication; and | 
      
      
        | 
           
			 | 
                           (D)  the proposed course of the medication; | 
      
      
        | 
           
			 | 
                     (3)  the resident and, if appropriate, the person  | 
      
      
        | 
           
			 | 
        authorized by law to consent on behalf of the resident are informed  | 
      
      
        | 
           
			 | 
        in writing that consent may be revoked; and | 
      
      
        | 
           
			 | 
                     (4)  the consent is evidenced in the resident's  | 
      
      
        | 
           
			 | 
        clinical record by: | 
      
      
        | 
           
			 | 
                           (A)  a signed form prescribed by the facility or  | 
      
      
        | 
           
			 | 
        by a statement of the person prescribing the medication or that  | 
      
      
        | 
           
			 | 
        person's designee that documents that consent was given by the  | 
      
      
        | 
           
			 | 
        appropriate person and the circumstances under which the consent  | 
      
      
        | 
           
			 | 
        was obtained; and | 
      
      
        | 
           
			 | 
                           (B)  the original or a copy of the written consent  | 
      
      
        | 
           
			 | 
        required by Subsection (c-1), if applicable. | 
      
      
        | 
           
			 | 
               (c-1)  In addition to the requirements of Subsection (c),  | 
      
      
        | 
           
			 | 
        consent to the prescription of an antipsychotic or neuroleptic  | 
      
      
        | 
           
			 | 
        medication is valid only if the consent to the prescription of that  | 
      
      
        | 
           
			 | 
        medication is given in writing, on a form prescribed by the  | 
      
      
        | 
           
			 | 
        commission, by a resident or by a person authorized by law to  | 
      
      
        | 
           
			 | 
        consent on behalf of the resident. | 
      
      
        | 
           
			 | 
               (c-2)  Written consent provided by a resident or the  | 
      
      
        | 
           
			 | 
        resident's legally authorized representative on the form described  | 
      
      
        | 
           
			 | 
        by Subsection (c-1) is presumed to satisfy the consent requirements  | 
      
      
        | 
           
			 | 
        of Subsection (c) and the disclosure requirements established by  | 
      
      
        | 
           
			 | 
        the Texas Medical Disclosure Panel in Sections 74.103 and 74.105,  | 
      
      
        | 
           
			 | 
        Civil Practice and Remedies Code. | 
      
      
        | 
           
			 | 
               SECTION 2.  As soon as practicable after the effective date  | 
      
      
        | 
           
			 | 
        of this Act, the executive commissioner of the Health and Human  | 
      
      
        | 
           
			 | 
        Services Commission shall develop the form required by Section  | 
      
      
        | 
           
			 | 
        242.505(c-1), Health and Safety Code, as added by this Act.  In  | 
      
      
        | 
           
			 | 
        developing the form, the commission shall consult with the Texas  | 
      
      
        | 
           
			 | 
        Medical Disclosure Panel. | 
      
      
        | 
           
			 | 
               SECTION 3.  This Act takes effect September 1, 2019. | 
      
      
        | 
           
			 | 
         | 
      
      
        | 
           
			 | 
        * * * * * |